首页> 外国专利> NOVEL IMIDAZOLIDINE DERIVATIVES THEIR PREPARATION THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM

NOVEL IMIDAZOLIDINE DERIVATIVES THEIR PREPARATION THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM

机译:新型咪唑啉衍生物可用于制备它们的用途和组成它们的药物制剂

摘要

Imidazolidine derivatives of formula (I) and their stereoisomers and salts are new. W = C(R13)AR1 or C=CHR1; Z = O or S; a = direct bond or 1-2C alkylene; B = 1-6C alkylene (optionally substituted by 1-8C alkyl), 2-8C alkenyl, 2-8C alkynyl, 3-10C cycloalkyl, (3-10C)cycloalkyl(1-6C)alkyl, optionally substituted 6-14C aryl, optionally ring-substituted (6-14C)aryl(1-6C)alkyl, optionally substituted heteroaryl or optionally ring-substituted heteroaryl(1-6C)alkyl, 2-6C alkenylene, phenylene, phenylene(1-3C)alkylene or (1-3C)alkylenephenylene; E = tetrazolyl, PO(OR8)2, SO3H, SO2NHR9 or COR10; R = H, 1-8C alkyl, 3-12C cycloalkyl, (3-12C)cycloalkyl(1-8C)alkyl, optionally substituted 6-14C aryl, optionally ring-substituted (6-14C)aryl(1-8C)alkyl, optionally substituted heteroaryl or optionally ring-substituted heteroaryl(1-8C)alkyl; R10 = H, R', CHO, COR', SOR' or SO2R'; R' = 1-8C alkyl, 3-12C cycloalkyl, (3-12C)cycloalkyl(1-8C)alkyl, 6-12C bicycloalkyl, (6-12C)bicycloalkyl(1-8C)alkyl, 6-12C tricycloalkyl, (6-12C)tricycloalkyl(1-8C)alkyl, optionally substituted 6-14C aryl, optionally ring-substituted (6-14C)aryl(1-8C)alkyl, optionally substituted heteroaryl or optionally ring-substituted heteroaryl(1-8C)alkyl; R1 = optionally substituted and optionally benzo-fused phenyl, furyl, thienyl, pyrrolyl, imidazolyl or pyridyl; R2 = H, 1-8C alkyl, optionally substituted 6-14C aryl, optionally ring-substituted (6-14C)aryl(1-8C)alkyl or 3-8C cycloalkyl; R3 = H, 1-8C alkyl, optionally substituted 6-14C aryl, optionally ring-substituted (6-14C)aryl(1-8C)alkyl, optionally substituted heteroaryl, optionally ring-substituted heteroaryl(1-8C)alkyl, 3-8C cycloalkyl, (3-8C)cycloalkyl(1-8C)alkyl, 6-12C bicycloalkyl, (6-12C)bicycloalkyl(1-8C)alkyl, 6-12C tricycloalkyl, (6-12C)tricycloalkyl(1-8C)alkyl, 2-8C alkenyl, 2-8C alkynyl, NHR11, CON(Me)R4, CONHR4, COOR14, CON(Me)R15 or CONHR15; R4 = H or 1-10C alkyl (optionally substituted by one or more of OH, 1-8C alkyl, R5, optionally substituted 3-8C cycloalkyl, COOH, CONH2, mono- or di(1-18C alkyl)carbamoyl, optionally ring-substituted (6-14C)aryl(2-9C)alkoxycarbonyl, 2-9C alkoxycarbonyl, CO-Het, COR6, tetrazolyl and CF3); R5 = optionally substituted 6-14C aryl, optionally ring-substituted (6-14C)aryl(1-8C)alkyl or optionally substituted mono- or bicyclic 5-12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O and S; R6 = optionally protected residue of an amino acid, imino acid, optionally N-(1-8C)-alkylated or N-(optionally ring-substituted (6-14)aryl(1-8C)alkylated) aza-amino acid or a dipeptide (optionally in ester or amide form); R8 = H, 1-18C alkyl optionally substituted 6-14C aryl or optionally ring-substituted (6-14C)aryl(1-8C)alkyl; R9 = H, CONH2, (1-18C alkyl)carbamoyl, (3-8C cycloalkyl)carbamoyl, optionally substituted (6-14C aryl)carbamoyl, 1-18C alkyl, optionally substituted 6-14C aryl or 3-8C cycloalkyl; R10 = OH, 1-18C alkoxy, optionally ring-substituted (6-14C)aryl(1-8C)alkoxy, optionally substituted 6-14C aryloxy, (2-9C)alkanoyloxy(1-6C)alkoxy, (7-15C)aroyloxy(1-6C)alkoxy, NH2 or mono- or di(1-18C alkyl)amino; R11 = H, R12a, COR12a, CHO, COOR12a, COR12b, CSR12b, SO2R12a or SO2R12b; R12a = 1-18C alkyl, 2-8C alkenyl, 2-8C alkynyl, 3-12C cycloalkyl, (3-12C)cycloalkyl(1-8C)alkyl, optionally substituted 6-14C aryl, optionally ring-substituted (6-14C)aryl(1-8C)alkyl, optionally substituted heteroaryl, optionally ring-substituted heteroaryl(1-8C)alkyl or R15; R12b = NH2, di(1-18C alkyl)amino or NHR12a; R13 = H, 1-6C alkyl, optionally substituted 6-14C aryl, optionally ring-substituted (6-14C)aryl(1-6C)alkyl, 3-8C cycloalkyl or (3-8C)cycloalkyl(1-6C)alkyl; R15 = R16 or 1-6C alkyl substituted by R16; R16 = 6-24-membered bicyclic or tricyclic group that is saturated or partially unsaturated, optionally contains 1-4 heteroatoms selected from N, O and S and is optionally substituted by one or more of 1-4C alkyl and oxo; Het = N-bonded 5-10-membered saturated mono- or polycyclic heterocyclic group that can contain 1-4 additional heteroatoms selected from O, N and S, can be C-substituted and can be substituted on additional N atoms by H, Rh, CHO, CORh or COORh; Rh = 1-8C alkyl, 3-8C cycloalkyl, (3-8C)cycloalkyl(1-8C)alkyl, optionally substituted 6-14C aryl or optionally ring-substituted (6-14C)aryl(1-8C)alkyl; and e, h = 0 or 1.
机译:式(I)的咪唑烷衍生物及其立体异构体和盐是新的。 W = C(R13)AR1或C = CHR1; Z = O或S; a =直接键或1-2C亚烷基; B = 1-6C亚烷基(可选被1-8C烷基取代),2-8C烯基,2-8C炔基,3-10C环烷基,(3-10C)环烷基(1-6C)烷基,可选取代的6-14C芳基,任选环取代的(6-14C)芳基(1-6C)烷基,任选取代的杂芳基或任选环取代的杂芳基(1-6C)烷基,2-6C亚烯基,亚苯基,亚苯基(1-3C)亚烷基或( 1-3C)亚烷基亚苯基; E =四唑基,PO(OR8)2,SO3H,SO2NHR9或COR10; R = H,1-8C烷基,3-12C环烷基,(3-12C)环烷基(1-8C)烷基,任选取代的6-14C芳基,任选环取代的(6-14C)芳基(1-8C)烷基,任选取代的杂芳基或任选环取代的杂芳基(1-8C)烷基; R10 = H,R',CHO,COR',SOR'或SO2R'; R'= 1-8C烷基,3-12C环烷基,(3-12C)环烷基(1-8C)烷基,6-12C双环烷基,(6-12C)双环烷基(1-8C)烷基,6-12C三环烷基,( 6-12C)三环烷基(1-8C)烷基,任选取代的6-14C芳基,任选环取代的(6-14C)芳基(1-8C)烷基,任选取代的杂芳基或任选环取代的杂芳基(1-8C)烷基; R1 =任选取代的和任选苯并稠合的苯基,呋喃基,噻吩基,吡咯基,咪唑基或吡啶基; R 2 = H,1-8C烷基,任选取代的6-14C芳基,任选环取代的(6-14C)芳基(1-8C)烷基或3-8C环烷基; R 3 = H,1-8C烷基,任选取代的6-14C芳基,任选环取代的(6-14C)芳基(1-8C)烷基,任选取代的杂芳基,任选环取代的杂芳基(1-8C)烷基,3 -8C环烷基,(3-8C)环烷基(1-8C)烷基,6-12C双环烷基,(6-12C)双环烷基(1-8C)烷基,6-12C三环烷基,(6-12C)三环烷基(1-8C )烷基,2-8C烯基,2-8C炔基,NHR11,CON(Me)R4,CONHR4,COOR14,CON(Me)R15或CONHR15; R4 = H或1-10C烷基(任选地被一个或多个OH,1-8C烷基,R5,任选取代的3-8C环烷基,COOH,CONH2,单或二(1-18C烷基)氨基甲酰基,任选地环取代-取代的(6-14C)芳基(2-9C)烷氧羰基,2-9C烷氧羰基,CO-Het,COR6,四唑基和CF3); R 5 =任选地取代的含有1-3个选自N,O和S的杂原子的6-14C芳基,任选地环取代的(6-14C)芳基(1-8C)烷基或任选地取代的单环或双环5-12元杂环基; R 6 =氨基酸的任选保护的残基,亚氨基酸,任选地N-(1-8C)-烷基化或N-(任选地环取代的(6-14)芳基(1-8C)烷基化)氮杂氨基酸或二肽(可选为酯或酰胺形式); R8 = H,1-18C烷基,任选取代的6-14C芳基或任选环取代的(6-14C)芳基(1-8C)烷基; R9 = H,CONH2,(1-18C烷基)氨基甲酰基,(3-8C环烷基)氨基甲酰基,任选取代的(6-14C芳基)氨基甲酰基,1-18C烷基,任选取代的6-14C芳基或3-8C环烷基; R10 = OH,1-18C烷氧基,任选环取代的(6-14C)芳基(1-8C)烷氧基,任选取代的6-14C芳氧基,(2-9C)烷酰氧基(1-6C)烷氧基,(7-15C )芳酰氧基(1-6C)烷氧基,NH 2或单或二(1-18C烷基)氨基; R11 = H,R12a,COR12a,CHO,COOR12a,COR12b,CSR12b,SO2R12a或SO2R12b; R12a = 1-18C烷基,2-8C烯基,2-8C炔基,3-12C环烷基,(3-12C)环烷基(1-8C)烷基,任选取代的6-14C芳基,任选环取代的(6-14C )芳基(1-8C)烷基,任选取代的杂芳基,任选环取代的杂芳基(1-8C)烷基或R 15; R12b = NH2,二(1-18C烷基)氨基或NHR12a; R13 = H,1-6C烷基,任选取代的6-14C芳基,任选环取代的(6-14C)芳基(1-6C)烷基,3-8C环烷基或(3-8C)环烷基(1-6C)烷基; R15 = R16或被R16取代的1-6C烷基; R16 = 6-24元饱和或部分不饱和的双环或三环基团,任选地含有1-4个选自N,O和S的杂原子,并任选地被1-4C烷基和氧代一个或多个取代; Het =可以包含1-4个选自O,N和S的其他杂原子的N键结合的5-10元饱和单环或多环杂环基,可以被C取代,并可以在其他N个原子上被H,Rh取代,CHO,CORh或COORh; Rh = 1-8C烷基,3-8C环烷基,(3-8C)环烷基(1-8C)烷基,任选取代的6-14C芳基或任选环取代的(6-14C)芳基(1-8C)烷基;并且e,h = 0或1。

著录项

  • 公开/公告号IL126247A

    专利类型

  • 公开/公告日1999-05-09

    原文格式PDF

  • 申请/专利权人 SANOFI-AVENTIS DEUTSCHLAND GMBH;

    申请/专利号IL126247

  • 发明设计人

    申请日1998-09-16

  • 分类号6C07KA;

  • 国家 IL

  • 入库时间 2022-08-22 02:27:08

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号